ArticleFrontiers in oncology2023
Deep learning-based immunohistochemical estimation of breast cancer via ultrasound image applications.
Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence in digital pathology diagnosis and analysis: technologies, challenges, and future prospects.Military Medical Research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the key global menace to women's health, which ranks first by mortality rate. The rate reduction and early diagnostics of breast cancer are the mainstream of medical research. Immunohistochemical examination is the most important link in the process of breast cancer treatment, and its results directly affect physicians' decision-making on follow-up medical treatment. Purpose: This study aims to develop a computer-aided diagnosis (CAD) method based on deep learning to classify breast ultrasound (BUS) images according to immunohistochemical results. Methods: A new depth learning framework guided by BUS image data analysis was proposed for the classification of breast cancer nodes in BUS images. The proposed CAD classification network mainly comprised three innovation points. First, a multilevel feature distillation network (MFD-Net) based on CNN, which could extract feature layers of different scales, was designed. Then, the image features extracted at different depths were fused to achieve multilevel feature distillation using depth separable convolution and reverse depth separable convolution to increase convolution depths. Finally, a new attention module containing two independent submodules, the channel attention module (CAM) and the spatial attention module (SAM), was introduced to improve the model classification ability in channel and space. Results: A total of 500 axial BUS images were retrieved from 294 patients who underwent BUS examination, and these images were detected and cropped, resulting in breast cancer node BUS image datasets, which were classified according to immunohistochemical findings, and the datasets were randomly subdivided into a training set (70%) and a test set (30%) in the classification process, with the results of the four immune indices output simultaneously from training and testing, in the model comparison experiment. Taking ER immune indicators as an example, the proposed model achieved a precision of 0.8933, a recall of 0.7563, an F1 score of 0.8191, and an accuracy of 0.8386, significantly outperforming the other models. The results of the designed ablation experiment also showed that the proposed multistage characteristic distillation structure and attention module were key in improving the accuracy rate. Conclusion: The extensive experiments verify the high efficiency of the proposed method. It is considered the first classification of breast cancer by immunohistochemical results in breast cancer image processing, and it provides an effective aid for postoperative breast cancer treatment, greatly reduces the difficulty of diagnosis for doctors, and improves work efficiency.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.